BackBridgeBio Oncology Therapeutics Overview
BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Target Price

See BridgeBio Oncology Therapeutics's analyst price targets ($19) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$1.81

Average Target Price

$19.00949.7% upside

3 analysts in the last 4 months

High: $22 | Low: $15

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-09Raymond JamesSean McCutcheon$221115.5% upsideOpen
2026-09-09Stifel Nicolaus$15728.7% upsideOpen
2026-09-09Canaccord Genuity$201005% upsideOpen
2026-05-11Canaccord GenuityJohn Newman$231170.7% upsideOpen
2026-02-10Stifel NicolausLaura Prendergast$231170.7% upsideOpen
2026-01-09Raymond James$241226% upsideOpen
2026-01-08Morgan Stanley$18894.5% upsideOpen
2025-12-05Morgan Stanley$201005% upsideOpen
2025-09-17Leerink Partners$251281.2% upsideOpen
2025-09-15H.C. WainwrightRobert Burns$271391.7% upsideOpen
2025-09-04Oppenheimer$231170.7% upsideOpen
2025-08-15Piper SandlerBiren Amin$211060.2% upsideOpen

BridgeBio Oncology Therapeutics (BBOT) FAQ

As of the most recent data, BBOT shows a target price of $19. Scroll down for historical charts and peer comparison views.

If BridgeBio Oncology Therapeutics moved to the average analyst target of $19, shares would be roughly 949.7% higher than $1.81. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of BridgeBio Oncology Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has BridgeBio Oncology Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $19) with ownership activity and broader fundamentals.

Questions & Answers